Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Resmed (RSMDF) over the last 16 years, with Q4 2025 value amounting to $147.5 million.

  • Resmed's Gains from Investment Securities rose 2435.71% to $147.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $199.1 million, marking a year-over-year decrease of 3954.68%. This contributed to the annual value of $214.0 million for FY2025, which is 2312.75% down from last year.
  • Resmed's Gains from Investment Securities amounted to $147.5 million in Q4 2025, which was up 2435.71% from $61.9 million recorded in Q3 2025.
  • Resmed's 5-year Gains from Investment Securities high stood at $345.9 million for Q3 2021, and its period low was -$26.5 million during Q1 2025.
  • For the 5-year period, Resmed's Gains from Investment Securities averaged around $74.0 million, with its median value being $54.0 million (2022).
  • Per our database at Business Quant, Resmed's Gains from Investment Securities soared by 353436.52% in 2021 and then tumbled by 14290.06% in 2025.
  • Quarter analysis of 5 years shows Resmed's Gains from Investment Securities stood at $37.0 million in 2021, then soared by 47.45% to $54.5 million in 2022, then surged by 77.25% to $96.7 million in 2023, then increased by 22.71% to $118.6 million in 2024, then grew by 24.36% to $147.5 million in 2025.
  • Its Gains from Investment Securities stands at $147.5 million for Q4 2025, versus $61.9 million for Q3 2025 and $16.2 million for Q2 2025.